Search results
Results from the WOW.Com Content Network
The Doha Declaration received positive reception, with many public health officials considering it an important step in prioritizing public health over intellectual property rights "in certain situations." [6] However, other issues and hindrances to medication access still exist, such as a lack of resources and infrastructure. [6]
The Doha Declaration on Public Health sought to alleviate developing country dissatisfaction with aspects of the TRIPS regime. It delayed the implementation of patent system provisions for pharmaceutical products for least developed countries (LDCs) until 2016. The declaration committed member states to interpret and implement the agreement to ...
In 2003, after two years of contentious negotiations,217 the TRIPS Council adopted the Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health [the “Waiver Decision”], under which it instituted a temporary “waiver” allowing WTO members to grant compulsory licenses free from the obligations imposed ...
The Doha Declaration on the TRIPS Agreement and Public Health, effective November 2001, was adopted by WTO Ministerial Conference of 2001. Many argued that the TRIPS Agreement hindered developing countries from implementing measures to improve access to affordable medicines, especially for diseases of public health concern, such as HIV ...
The Doha Declaration on the TRIPS Agreement and Public Health is adopted by the WTO Ministerial Conference of 2001 in Doha on November 14, 2001. It reaffirms flexibility of TRIPS member states in circumventing patent rights for better access to essential medicines .
Doha conference can refer to several meetings held in Doha, Qatar: The WTO Ministerial Conference of 2001. leading to the Doha Development Round; and the Doha Declaration on the TRIPS Agreement and Public Health; 2008 follow-up conference to the Monterrey Consensus; Doha Agreement (2008) between rival Lebanese factions; Hamas–Fatah Doha ...
A major topic at the Doha ministerial regarded the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The issue involves the balance of interests between the pharmaceutical companies in developed countries that held patents on medicines and the public health needs in developing countries. Another issue concerns the ...
Despite the role that patents have played in maintaining higher drug costs for public health programs across Africa, this controversy has not led to a revision of TRIPS. Instead, an interpretive statement, the Doha Declaration , was issued in November 2001, which indicated that TRIPS should not prevent states from dealing with public health ...